The ClC-2 Chloride Channel Activator, Lubiprostone, Improves Intestinal Barrier Function in Biopsies from Crohn’s Disease but Not Ulcerative Colitis Patients
Young Su Park(Seoul National University), Declan F. McCole(University of California, Riverside), Brigid S. Boland, Sang‐Bum Kang(University of California San Diego), William J. Sandborn(University of San Diego), Barbara Jung(University of California San Diego), Roos Ruiter-Visser(Radboud University Nijmegen), Ronald R. Marchelletta(Merck & Co., Inc., Rahway, NJ, USA (United States)), Michael J. Docherty(University of California San Diego), Harrison M. Penrose(University of California San Diego)
Cited by 10
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Crohn's disease
|The Lancet|2012|2.1k